Table 2 Subgroup analysis to assess the effect of SFN supplement on lipid profile.
From: Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis
Effect size, n | WMD | 95% CI | I-squared (%) | P for heterogeneity | P for between subgroup heterogeneity | |
|---|---|---|---|---|---|---|
Body weight | ||||||
Overall effect | 6 | − 2.76 | − 4.19, − 1.34 | 58.9 | 0.032 | |
Species | 0.471 | |||||
Mice | 3 | − 2.93 | − 4.34, − 1.52 | 76.3 | 0.015 | |
Rats | 3 | 1.12 | − 6.87, 9.10 | 24.8 | 0.265 | |
Disease model | 0.122 | |||||
Obesity (without STZ) | 4 | − 3.30 | − 4.46, − 2.14 | 52.7 | 0.096 | |
Diabetes (with STZ) | 2 | 1.09 | − 4.53, 6.72 | 12.2 | 0.286 | |
Duration | 0.122 | |||||
≤ 10 weeks | 4 | − 3.18 | − 4.60, − 1.75 | 64.6 | 0.037 | |
> 10 weeks | 2 | − 0.45 | − 3.68, 2.79 | 0.0 | 0.37 | |
SFN dosage | 0.292 | |||||
≤ 0.5 mg/kg/day | 2 | 1.09 | − 4.53, 6.72 | 12.2 | 0.286 | |
> 0.5 mg/kg/day | 4 | − 3.30 | − 4.46, − 2.14 | 52.7 | 0.096 | |
Administration route | 0.391 | |||||
Oral | 3 | − 3.96 | − 4.47, − 3.14 | 0.0 | 0.392 | |
Injection | 3 | − 1.33 | − 4.46, 1.80 | 55.2 | 0.107 | |
Liver weight | ||||||
Overall effect | 4 | − 0.93 | − 1.63, − 0.23 | 93.0 | 0.000 | |
Species | 0.712 | |||||
Mice | 1 | − 0.54 | − 0.75, − 0.33 | – | – | |
Rats | 3 | − 1.11 | − 2.31, 0.09 | 95.2 | 0.000 | |
Disease model | 0.363 | |||||
Obesity (without STZ) | 3 | − 1.26 | − 2.13, − 0.39 | 93.3 | 0.000 | |
Diabetes (with STZ) | 1 | 0.00 | − 0.37, 0.37 | – | – | |
Duration | 0.992 | |||||
≤ 10 weeks | 3 | − 0.93 | − 1.89, 0.03 | 94.9 | 0.000 | |
> 10 weeks | 1 | − 1.00 | − 1.40, − 0.60 | – | – | |
SFN dosage | 0.363 | |||||
≤ 0.5 mg/kg/day | 1 | 0.00 | − 0.37, 0.37 | – | – | |
> 0.5 mg/kg/day | 3 | − 1.26 | − 2.13, − 0.39 | 93.3 | 0.000 | |
Administration route | 0.363 | |||||
Oral | 3 | − 1.26 | − 2.13, − 0.39 | 93.3 | 0.000 | |
Injection | 1 | 0.00 | − 1.63, − 0.23 | – | – | |
Total cholesterol | ||||||
Overall effect | 6 | − 15.62 | − 24.07, − 7.18 | 92.3 | 0.000 | |
Species | 0.511 | |||||
Mice | 2 | − 23.59 | − 60.48, 13.30 | 97.3 | 0.000 | |
Rats | 4 | − 12.77 | − 21.41, − 4.14 | 89.2 | 0.000 | |
Disease model | 0.752 | |||||
Obesity (without STZ) | 4 | − 17.49 | − 30.34, − 4.64 | 93.7 | 0.000 | |
Diabetes (with STZ) | 2 | − 12.92 | − 28.45, 2.61 | 94.3 | 0.000 | |
Duration | 0.261 | |||||
≤ 10 weeks | 4 | − 21.27 | − 34.67, − 7.87 | 92.5 | 0.000 | |
> 10 weeks | 2 | − 6.17 | − 9.01, − 3.34 | 0.0 | 0.525 | |
SFN dosage | 0.338 | |||||
≤ 0.5 mg/kg/day | 3 | − 9.66 | − 20.10, 0.78 | 90.6 | 0.000 | |
> 0.5 mg/kg/day | 3 | − 22.75 | − 40.46, − 5.04 | 95.1 | 0.000 | |
Administration route | 0.752 | |||||
Oral | 4 | − 17.49 | − 30.34, − 4.64 | 93.7 | 0.000 | |
Injection | 2 | − 12.92 | − 28.45, 2.61 | 94.3 | 0.000 | |
HDL-C | ||||||
Overall effect | 5 | 1.05 | − 3.44, 5.54 | 91.2 | 0.000 | |
Species | 0.199 | |||||
Mice | 1 | − 8.30 | − 11.94, − 4.66 | – | – | |
Rats | 4 | 3.31 | − 1.18, 7.80 | 88.0 | 0.000 | |
Disease model | 0.747 | |||||
Obesity (without STZ) | 4 | 0.40 | − 5.42, 6.22 | 92.5 | 0.000 | |
Diabetes (with STZ) | 1 | 4.00 | 0.65, 7.35 | – | – | |
Duration | 0.878 | |||||
≤ 10 weeks | 4 | 1.63 | − 6.44, 9.70 | 93.4 | 0.000 | |
> 10 weeks | 1 | 0.00 | − 0.40, 0.40 | – | – | |
SFN dosage | 0.102 | |||||
≤ 0.5 mg/kg/day | 2 | 8.26 | − 0.71, 17.22 | 85.9 | 0.008 | |
> 0.5 mg/kg/day | 3 | − 3.13 | − 8.38, 2.12 | 90.1 | 0.000 | |
Administration route | 0.747 | |||||
Oral | 4 | 0.40 | − 5.42, 6.22 | 92.5 | 0.000 | |
Injection | 1 | 4.00 | 0.65, 7.35 | – | – | |
Triglyceride | ||||||
Overall effect | 5 | − 40.85 | − 67.46, − 14.24 | 97.1 | 0.000 | |
Species | 0.659 | |||||
Mice | 2 | − 41.49 | − 161.29, 78.30 | 98.7 | 0.000 | |
Rats | 3 | − 33.14 | − 60.77, − 5.51 | 95.3 | 0.000 | |
Disease model | 0.092 | |||||
Obesity (without STZ) | 3 | − 1.34 | − 18.69, 16.01 | 95.1 | 0.000 | |
Diabetes (with STZ) | 2 | − 212.55 | − 436.50, 11.40 | 97.1 | 0.000 | |
Duration | 0.898 | |||||
≤ 10 weeks | 4 | − 18.05 | − 42.06, 5.96 | 96.4 | 0.000 | |
> 10 weeks | 1 | − 103.25 | − 128.94, − 77.56 | – | – | |
SFN dosage | 0.305 | |||||
≤ 0.5 mg/kg/day | 3 | − 132.41 | − 231.71, − 33.12 | 97.5 | 0.000 | |
> 0.5 mg/kg/day | 2 | 4.85 | − 22.42, 32.13 | 97.1 | 0.000 | |
Administration route | 0.092 | |||||
Oral | 3 | − 1.34 | − 18.69, 16.01 | 95.1 | 0.000 | |
Injection | 2 | − 212.55 | − 436.50, 11.40 | 94.9 | 0.000 | |
